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It is estimated that 2 - 3% of children will be 
hospitalised with viral bronchiolitis during 
their first year of life, and a small proportion 
of them will have a severe course of the 
disease (Table 1), requiring intensive care 
and ventilatory support.[1-3] Risk factors for 
severe disease include a history of prematurity; 
underlying chronic conditions such as bron-
chopulmonary dysplasia, neuromuscular 
disease, and congenital heart diseases; lack of 
breastfeeding; poor socioeconomic circum-
stances; and immunosuppression, including 
HIV/AIDS.[4]
Aetiology and 
co-infection
In South Africa (SA), 20% of children admitted 
to a paediatric intensive care unit (PICU) were 
reported to have positive respiratory viral 
isolates, with symptomatic respiratory disease.[5] 
The most common viruses occurring in the 
PICU context in SA are human rhinovirus, 
respiratory syncytial virus (RSV), adenovirus, 
influenza and para-influenza viruses, and 
human metapneumovirus (hMPV).[5,6]
The importance of human rhinovirus has 
previously been under estimated, but is now 
known to be a pathogen with the potential to 
cause severe disease in both PICU and neona-
tal ICU (NICU) popu lations, with a prevalence 
of up to 40% in emergency department and 
hospital settings.[7,8] In a case controlled study 
of children after cardiac surgery, human rhino-
virus infect ion was associated with a twelvefold 
increase in the probability of extubation failure, 
a threefold increase in duration of PICU stay, 
and a twofold increase in length of hospital 
stay.[9] It has been suggested that when human 
rhinovirus is detected by polymerase chain 
reaction (PCR) in symptomatic individuals, it 
is likely to represent true infection.[10]
hMPV has been reported in up to 19% of 
hospitalised SA children with respiratory tract 
infections (RTIs).[11,12] hMPV is asso ciated with 
significant morbidity, with similar presentation 
and outcome to RSV infection.[12]
In the PICU, co-infection with bacteria 
and other potential pathogens (e.g. fungi, 
Pneumocystis jirovecii) is common.[5] Recently, 
nosocomial acquisition of viral RTI has been 
highlighted as a potentially serious problem, 
particularly in the context of limited cohorting 
and isolation facilities in SA and other develop-
ing countries.[5,6,13,14] The importance of infec-
tion control measures, including hand wash-
ing, surface cleaning, isolation, and cohorting 
must be emphasised to prevent nosocomial 
spread of respiratory viruses.[15]
Rapid laboratory-based diagnosis using 
multiplex PCR is recom mended to reduce 
overall antibiotic use in the PICU and 
NICU and to improve the targeted use of 
antibiotics (antibiotic stewardship), as well 
as early identification of potential outbreaks 
to ensure containment and limit nosocomial 
transmission.[16,17]
Management of 
bronchiolitis in the 
PICU and NICU
The mainstay of bronchiolitis management in 
the PICU and NICU is supportive, compris-
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Table 1. Assessment of bronchiolitis severity in infants[4]
Observations
Mild 
bronchiolitis
Moderate 
bronchiolitis
Severe 
bronchiolitis
Feeding Normal Less than usual Not interested
Respiratory rate, 
breaths/min
<2 mo, >60
>2 mo, >50
>60 >70
Chest wall recessions Mild Moderate Severe
Nasal flare or grunting Absent Absent Present
Oxygen saturation, % >92 88 - 92 <88
General behaviour Normal Irritable Lethargic
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ing fluid management, oxygen supplementa-
tion and/or respiratory ventilatory support, 
and antipyretics if needed.[17,18]
Ventilatory support
Mechanical ventilation for bronchiolitis was 
first described in the 1960s, when it markedly 
decreased mortality associated with respiratory 
failure.[19] However, numerous complications of 
intubation and mechanical ventilation are now 
described, including ventilator-induced lung 
injury, ventilator-associated pneumonia, and 
tracheal stenosis.[20] In a prospective observa-
tional multicentre study,[21] endotracheal intu-
bation and mechanical ventilation were shown 
to cause a marked increase in pulmonary 
inflammation in infants with severe RSV bron-
chiolitis. The avoidance of intubation and inva-
sive mechanical ventilation as far as possible is 
therefore optimal in terms of lung protection, 
but they may be necessary in severe disease.
Non-invasive nasal continuous positive air-
way pressure (nCPAP) and high-flow nasal 
cannula (HFNC) oxygen therapy are increas-
ingly being used in children with severe bron-
chiolitis, and may reduce the need for intuba-
tion.[22–24] Furthermore, these technologies may 
provide the only form of ventilatory support 
in areas where children with severe bronchi-
olitis cannot access mechanical ventilation.[23] 
nCPAP may reduce the work of breathing by 
preventing dynamic airway collapse, thereby 
potentially reducing air trapping and improv-
ing gaseous exchange, although there may also 
be a risk of overinflation.[25] HFNC has been 
shown to increase end-expiratory lung vol-
umes and reduce respiratory rate in infants with 
bronchiolitis, and may be better tolerated than 
nCPAP.[26,27] However, systematic reviews have 
not yielded conclusive results as to whether 
either technique reduces intubation rates, largely 
due to a lack of prospective randomised con-
trolled trials.[22,28] 
Even though there have been varying 
reports, there has been no consensus with 
regard to appropriate invasive mechanical 
ventilation strategies for infants with severe 
bronchiolitis. Pressure control or pressure-
regulated volume-controlled ventilation 
compared with volume-controlled ventila-
tion, may deliver lower tidal volumes than 
those programmed in high resistance situa-
tions, leading to hypoventilation;[29] there-
fore, volume-controlled modes should be 
considered in children with bronchiolitis.
Lung-protective ventilation, using a low 
tidal volume pressure-limited approach, is 
essential to limit ventilator-induced lung 
injury.[30] In an animal model of RSV RTI, 
low tidal volume mechanical ventilation 
caused less ventilation-induced cellular and 
cytokine influx into the bronchoalveolar 
space.[31] The key features of lung-protective 
ventilation are: 
• controlled oxygen exposure
• permissive hypercapnia
• low tidal volumes (4 - 6 mL/kg)
• adequate (but not excessive) positive end-
expiratory pressure 
• maintaining peak inspiratory pressures of 
<30 cmH2O.
Infants with bronchiolitis may have a 
variety of clinical presentations, which may 
require different ventilatory approaches 
(Fig. 1).[25,29,32] Children may predominantly 
present with apnoeas, air trapping and 
wheeze, atelectasis and parenchymal disease 
(in acute respiratory distress syndrome), or a 
combination of these.[25] 
Other therapies 
Recombinant human deoxyribonuclease 
(rhDNAse (Pulmozyme))[33] and glucocorti coids[34] 
are not recommended in the management 
of infants and children with bronchiolitis. 
Recommendations for the use of exogenous 
surfactant and heliox therapy are presented in 
Table 2.
Conclusion
Most cases of bronchiolitis in young infants 
and children are mild enough to manage 
conservatively at home or in general hospital 
wards. In exceptional cases, acute viral 
bronchiolitis may be so severe that it warrants 
admission of patients to the PICU for respiratory 
support and medical care. 
Table 2. Additional therapy in severe bronchiolitis
Therapy Effect Practice recommendation
Exogenous surfactant[34] Reduces PICU length of stay
Favourable effects on oxygenation and CO2 elimination 
Exogenous surfactant may be useful in selected patients
Larger trials needed before surfactant can be 
recommended as standard treatment
Heliox[35] If delivered effectively (only with tightly fitted facemask 
or CPAP), heliox therapy significantly reduced length 
of hospital treatment at different points of care (wards, 
PICU) 
Nasal cannula heliox therapy is ineffective 
RSV-positive infants responded better to heliox therapy
Heliox therapy could be considered for hospitalised infants 
with bronchiolitis, hypoxaemia and/or respiratory distress
If heliox therapy needs to be rationalised, it could be 
targeted to those who are RSV positive
Heliox therapy should only be delivered via a tight-fitting 
non-rebreathing facemask or CPAP
Primary presentation
Air trapping/
hyperination
Atelectasis and
parenchymal disease
Apnoeas
Use lung-protective
ventilation (as mentioned
above) to prevent
lung injury
Manage as ARDS using
lung-protective ventilation
(as mentioned above)
Consider high-frequency
oscillatory ventilation
if indicated
Manage as for asthma
Perhaps some advantage of
volume-targeted ventilation
strategies with constant ow
Minimise minute ventilation
Increase expiratory time with
adequate inspiration (I:E ratio >1:2)
Slow respiratory rate to avoid
air trapping
Accept lower pH
Allow permissive hypercapnia
Watch intrinsic PEEP 
Fig. 1. Invasive ventilation strategies for different presentations of severe bronchiolitis. (ARDS = acute 
respiratory distress syndrome; PEEP = positive end-expiratory pressure; I:E = inspiration:expiration.)
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